Overview
Q2 2018
Quarterly Results
Jun 30, 2018
Price
Change
MKT Cap
Volume
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Sign up for email alerts
Be the first to receive breaking news
Sign up today
Yuval Cohen, PhD
Chief Executive Officer, Director
Yuval Cohen, Ph.D., joined Corbus in July 2013 as Chief Executive Officer. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq CLTX) from 2005 to June 2013. Under Dr. Cohen's leadership, Celsus
View Full Bio
Mark A. Tepper, PhD
President & Chief Scientific Officer
Mark A. Tepper, Ph.D., co-founded the Company in 2009. He has more than twenty years of leadership experience in pharmaceutical R&D and his past roles include leadership positions at Bristol Myers Squibb, Serono, CytRx, RXi
View Full Bio
Barbara White, MD
Chief Medical Officer
Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and
View Full Bio
Sean Moran, CPA, MBA
Chief Financial Officer
Sean Moran, CPA, joined Corbus in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery and medical device companies. Mr. Moran has successfully managed operations from start
View Full Bio
Robert Discordia, Ph.D.
Vice President, Pharmaceutical Development & Manufacturing
Robert Discordia, Ph.D., joined Corbus as Vice President, Pharmaceutical Development & Manufacturing in May 2018. Dr. Discordia brings to Corbus more than 25 years of biopharmaceutical industry experience in CMC development and
View Full Bio
Ross Lobell
Vice President, Regulatory Affairs
Ross Lobell joined Corbus as Vice President, Regulatory Affairs in April 2018. Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory
View Full Bio
Alan Holmer
Chairman of the Board
Alan F. Holmer served from 1996 to 2005 as President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents the worldwide interests of leading pharmaceutical and
View Full Bio
Avery W. Catlin served (now retired) as Senior Vice President, Chief Financial Officer, and Secretary of Celldex Therapeutics, Inc., a public biopharmaceutical company. Prior to joining Celldex Therapeutics, Inc. in January 2000, he served
View Full Bio
Yuval Cohen, PhD
Chief Executive Officer, Director
Yuval Cohen, Ph.D., joined Corbus in July 2013 as Chief Executive Officer. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq CLTX) from 2005 to June 2013. Under Dr. Cohen's leadership, Celsus
View Full Bio
David Hochman is a Managing Partner of Orchestra Medical Ventures, an investment firm that employs an innovative strategy to create, build and invest in medical technology companies intended to generate substantial clinical value and
View Full Bio
John Jenkins, MD
Director
Dr. Jenkins served as the Director of the Office of New Drugs (OND) at U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017, where he was responsible for more than 1,000 agency
View Full Bio
Paris Panayiotopoulos
Director
Mr. Panayiotopoulos was most recently the President and Chief Executive Officer and a member of the Board of Directors of ARIAD Pharmaceuticals, Inc., which was acquired by Takeda Pharmaceuticals for $5.2 billion in February 2017. Prior to
View Full Bio
